MedTrace Logo

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

NCT00125762 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 907

Last updated 2017-10-27

Study results available
· View outcomes & findings →

Summary

This study will examine the effectiveness of the FibroScan device in differentiating fibrosis in patients with hepatitis B and C. The FibroScan measures liver stiffness and will be correlated to the liver biopsy to see if it can diagnose the stage of liver disease. Patients who are scheduled to have a liver biopsy will also have a fibroscan and the stiffness will be correlated with the biopsy stage.

Conditions

Interventions

DEVICE

FibroScan

Sponsors & Collaborators

  • Echosens

    collaborator INDUSTRY

  • Afdhal, Nezam, M.D.

    lead INDIV

Principal Investigators

  • Nezam H Afdhal, M.D. · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-05-01
Completion
2008-10-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125762 on ClinicalTrials.gov